Typewriter raises $56M to turn "jumping genes" into new therapies
What's the deal? TypewriterDealroom has a profile for this one. Try Dealroom → has raised $56 million to develop technology based on "jumping genes" — mobile pieces of genetic code — and to pursue in vivo CAR-T therapies. The company aims to use the approach to transplant full genes into human cells.
What's the endgame? Jumping genes could give scientists a long-sought way to insert entire genes, rather than making smaller edits. Typewriter is also targeting in vivo CAR-T, an approach that engineers immune cells directly inside the body rather than in a lab.
Why now? In vivo CAR-T has drawn growing investor interest as companies race to make cell therapies simpler and cheaper to deliver. Typewriter's raise, disclosed in September 2026, lands as capital continues to flow into next-generation gene and cell therapy platforms.
The signal: The funding reflects continued appetite for gene-insertion tools that go beyond conventional editing. If jumping-gene technology can reliably deliver full genes, it could widen the range of diseases that gene therapies can address.
Read more: endpoints.news
Image credit: Generated with Gemini
